dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination has been researched along with fluorexon in 1 studies
| Studies (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination) | Trials (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination) | Recent Studies (post-2010) (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination) | Studies (fluorexon) | Trials (fluorexon) | Recent Studies (post-2010) (fluorexon) |
|---|---|---|---|---|---|
| 219 | 84 | 3 | 1,452 | 4 | 489 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, R; Huilgol, N; Preetha, A | 1 |
1 other study(ies) available for dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination and fluorexon
| Article | Year |
|---|---|
Effect of fluidizing agents on paclitaxel penetration in cervical cancerous monolayer membranes.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Membrane Permeability; Drug Combinations; Fatty Alcohols; Female; Fluoresceins; Fluorescent Dyes; Humans; In Vitro Techniques; Liposomes; Membrane Fluidity; Membranes, Artificial; Models, Biological; Paclitaxel; Phospholipids; Phosphorylcholine; Polyethylene Glycols; Surface-Active Agents; Uterine Cervical Neoplasms | 2007 |